Showing results (101-110 of 146) with videos related to
Sort By:
Pageof 15
JAMA|January 16, 2019
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple SclerosisJ William L Brown, Alasdair Coles, Dana Horakova, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|July 23, 2015
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosisMatthew Warrender-Sparkes, Tim Spelman, Guillermo Izquierdo, et al.Brain : a Journal of Neurology|May 10, 2020
Early clinical markers of aggressive multiple sclerosisCharles B Malpas, Ali Manouchehrinia, Sifat Sharmin, et al.Journal of Neuroimmunology|July 22, 2025
Comparative efficacy of rituximab versus azathioprine in the treatment of MOG antibody-associated disease (MOGAD)Sedat Şen, Murat Kürtüncü, Serkan Demir, et al.Scientific Reports|April 5, 2025
Exome sequencing reveals low-frequency and rare variant contributions to multiple sclerosis susceptibility in Turkish familiesFurkan Büyükgöl, Berk Gürdamar, Mehmet Ufuk Aluçlu, et al.Journal of Neurology|January 8, 2026
Real-world effectiveness and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorderEmine Rabia Koc, Mehmet Fatih Yetkin, Furkan Saridas, et al.Computer Methods and Programs in Biomedicine|June 19, 2021
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progressionEdward De Brouwer, Thijs Becker, Yves Moreau, et al.Journal of Neurology, Neurosurgery, and Psychiatry|September 28, 2022
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data networkAlessio Signori, Johannes Lorscheider, Sandra Vukusic, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|April 7, 2017
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysisAlessio Signori, Guillermo Izquierdo, Alessandra Lugaresi, et al.Balkan Medical Journal|June 3, 2024
Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte GlycoproteinSümeyye Koç, Sedat Şen, Yüksel Terzi, et al.Pageof 15